학술논문
Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
Document Type
Article
Author
Source
춘·추계 학술대회(The Liver Week). Jun 24, 2017 2017(1):163
Subject
Language
Korean
Abstract
Aims: The AASLD/IDSA/IAS-USA Guidance and EASL Recommendations on Treatment of Hepatitis C state that HIV/HCV coinfection should be treated the same as HCV monoinfection with careful monitoring of antiretrovirals. Real world cohorts (RWC) have demonstrated excellent efficacy of LDV/SOF for 8weeks in HCV monoinfected patients. The aim of this study was to describe the effectiveness of the STR of LDV/SOF for 8 weeks in HCV GT 1 patients with HIV/HCV coinfection in RWC. Methods: Real world effectiveness data of LDV/SOF for 8weeks in HIV/HCV coinfection is emerging from multiple cohorts. In this descriptive analysis, data from two prospective studies, one investigator- sponsored, 1 registrational trial, and three retrospective RWC of LDV/SOF for 8weeks in HIV/HCV co-infected patients were compared. The prospective trials include data from Ain et al (investigator sponsored) and Isakov et al (registrational trial). The RWC include the Deutsches Hepatitis C-Register, Madrid Coinfection Registry (Madrid-CoRe), and Veterans Affairs HCV Registry. Baseline characteristics and efficacy were analyzed. Results: The majority of the 279 patients included in this descriptive analysis were GT1, treatment naive (TN), noncirrhotic (NC), and had a HCV viral load <6million. The prospective cohorts enrolled 79 patients with the following baseline characteristics: mean age (43 years), male (74%), white (78%), and GT1a (55%). The RWC studies assessed enrolled 200 patients with the following overall baseline characteristics: mean age (53 years) male (79%), white (98%), and GT1a (82%) in those that reported demographics. The overall SVR12 from five diverse real world and post-marketing cohorts was 94% (263/279). The individual study results are presented in Table 1. Conclusions: This analysis of diverse cohorts from the EU and US yielded high SVR rates similar to SVR rates seen in multiple RW moninfected cohorts and supports the use of 8 weeks of LDV/SOF in TN, NC GT 1 HIV/HCV coinfected patients with a baseline HCV viral load <6 million.